We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

47 hedge funds and large institutions have $16.5M invested in Ovid Therapeutics in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.29% less ownership

Funds ownership: 30.02% → 27.73% (-2.3%)

4% less funds holding

Funds holding: 49 → 47 (-2)

18% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 11

19% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 16

61% less capital invested

Capital invested by funds: $41.9M → $16.5M (-$25.4M)

Holders
47
Holders Change
-2
Holders Change %
-4.08%
% of All Funds
1.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
13
Reduced
16
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$7.3M
2
CI
Cowen Inc
New York
+$656K
3
JP Morgan Chase
JP Morgan Chase
New York
+$363K
4
Renaissance Technologies
Renaissance Technologies
New York
+$251K
5
Two Sigma Investments
Two Sigma Investments
New York
+$216K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.76M
2
O
OppenheimerFunds
New York
-$2.41M
3
BBA
Baker Bros. Advisors
New York
-$1.26M
4
DCM
Driehaus Capital Management
Illinois
-$1.2M
5
Deutsche Bank
Deutsche Bank
Germany
-$896K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$3.87M +$7.3M +1,600,000 New
BlackRock
2
BlackRock
New York
$3.42M -$333K -73,059 -5%
CI
3
Cowen Inc
New York
$2.06M +$656K +143,771 +20%
RG
4
Redmile Group
California
$1.78M +$33.8K +7,400 +1%
TCM
5
Tekla Capital Management
Massachusetts
$1.2M -$177K -38,847 -7%
Vanguard Group
6
Vanguard Group
Pennsylvania
$708K -$705K -154,510 -35%
State Street
7
State Street
Massachusetts
$411K -$63.7K -13,949 -8%
Northern Trust
8
Northern Trust
Illinois
$336K -$13.1K -2,862 -2%
JP Morgan Chase
9
JP Morgan Chase
New York
$325K +$363K +79,495 +145%
BCM
10
Bridgeway Capital Management
Texas
$238K -$45.6K -10,000 -9%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$231K +$29.2K +6,391 +7%
Dimensional Fund Advisors
12
Dimensional Fund Advisors
Texas
$211K +$41K +8,995 +11%
Jacobs Levy Equity Management
13
Jacobs Levy Equity Management
New Jersey
$191K +$205K +44,984 +132%
Charles Schwab
14
Charles Schwab
California
$142K -$5.55K -1,216 -2%
Renaissance Technologies
15
Renaissance Technologies
New York
$133K +$251K +55,100 New
Deutsche Bank
16
Deutsche Bank
Germany
$125K -$896K -196,420 -79%
Two Sigma Investments
17
Two Sigma Investments
New York
$114K +$216K +47,263 New
FC
18
Fairpointe Capital
Illinois
$99K +$187K +41,000 New
Morgan Stanley
19
Morgan Stanley
New York
$93K -$59.8K -13,099 -25%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$84K +$160 +35 +0.1%
Acadian Asset Management
21
Acadian Asset Management
Massachusetts
$68K – – –
Bank of America
22
Bank of America
North Carolina
$60K +$93.7K +20,525 +475%
OAM
23
Oxford Asset Management
United Kingdom
$57K +$107K +23,467 New
TCIM
24
TIAA CREF Investment Management
New York
$56K – – –
Millennium Management
25
Millennium Management
New York
$54K -$315K -68,947 -76%
1
2 3

OVID Hedge Fund Activity: Q4 2018 in Review

47 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q4 2018, worth a combined $16.5M — down 61% from $41.9M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of OVID and 9 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 13 added.

The largest buyer was Armistice Capital, opening a new position worth an estimated $7.3M. The largest seller was Fidelity Investments, exiting entirely with an estimated $5.76M sold.

  • 47 institutional investors held Ovid Therapeutics (OVID) as of Q4 2018, down from 49 in Q3 2018.
  • Funds reported $16.5M of Ovid Therapeutics stock for Q4 2018, down 61% quarter-over-quarter.
  • 9 funds opened new Ovid Therapeutics positions in Q4 2018 and 11 closed out, a net change of -2 holders.
  • The largest Ovid Therapeutics buyer in Q4 2018 was Armistice Capital, an estimated $7.3M added.
  • The largest Ovid Therapeutics seller in Q4 2018 was Fidelity Investments, an estimated $5.76M sold.

Based on aggregated 13F filings for Q4 2018.